Compare EVEX & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVEX | SANA |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | 198 | N/A |
| Industry | Aerospace | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.2M | 793.1M |
| IPO Year | N/A | 2021 |
| Metric | EVEX | SANA |
|---|---|---|
| Price | $2.40 | $3.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $6.88 | ★ $7.80 |
| AVG Volume (30 Days) | 965.7K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11,676.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $2.61 |
| 52 Week High | $6.83 | $6.55 |
| Indicator | EVEX | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 42.06 |
| Support Level | $2.33 | $3.03 |
| Resistance Level | $2.81 | $3.43 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 62.65 | 16.13 |
Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.